Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2021

View Archived Issues

Wnt/beta-catenin pathway blocker C644-0303 inhibits colorectal cancer growth

HCN targeting rescues chronic stress-induced cognitive deficits

Accutar Biotechnology patents EGFR and/or HER2 inhibitors

Merck & Co. divulges coagulation factor XIa inhibitors

PMV Pharmaceuticals identifies new TP53 mutant stabilizers

Bristol Myers Squibb synthesizes new galectin-3 inhibitors

J2H Biotech synthesizes new compounds for liver cancer

GAT-564, a novel CB1R allosteric modulator with efficacy in murine model of glaucoma

Orion completes OB-004 lead optimization

BCL10/MALT1 axis found to be involved in psoriasis

Novel selective c-Abl inhibitor prevents neurodegeneration in models of Parkinson's

CRISPRa-mediated SEC23A activation rescues SEC23B-deficient CDAII in vivo

Novel cyanobacterium-based approach for the treatment of colon cancer and colitis

Soligenix's bivalent thermostabilized vaccine protects NHPs against Sudan ebolavirus challenge

Novavax outlines vaccine response to SARS-CoV-2 Omicron variant

Newly identified variant has large effects on two aspects of cardiovascular risk

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...